Due to hormone receptor-positive and triple-negative breast cancer accounting for 80% of breast cancer cases and the high occurrence of BRCA1 in triple-negative breast cancer, a subgroup analysis of BiAMIL’s performance in these subtypes was conducted, with results shown in Table 2. This evidence concerns the gene NR4A1 and triple-negative breast carcinoma.